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Abstract. Immunity and cytokines serve crucial roles in 
cutaneous melanoma. The present study investigated whether 
a variable number tandem repeat (VNTR) polymorphism of 
interleukin-1 receptor antagonist (IL-1RA) gene (IL‑1RN) 
located in intron 2 (rs2234663) is associated with cutaneous 
melanoma. A total of 515 subjects were studied, 133 of which 
were cutaneous melanoma cases (72 stage I+II non-metastatic 
melanoma cases and 61 stage III+IV metastatic melanoma 
cases), and 382 subjects were matching healthy controls from 
the Friuli-Venezia-Giulia Region located in Northeast Italy, 
an area with a high melanoma incidence. The IL‑1RN‑VNTR 
polymorphism was determined by DNA fragment length 
analysis following PCR amplification. According to the 
number of 86‑bp repeats, five different IL‑1RN alleles were 
identified: Allele 1 (4‑repeats), allele 2 (2‑repeats, short allele), 
allele 3 (5-repeats), allele 4 (3-repeats) and allele 5 (6-repeats). 
Alleles with three or more 86-bp repeats, i.e. allele 1, 3, 4 and 
5 were collectively denoted as long (L) repeats. The present 
study revealed that IL‑1RN-VNTR 1/2 and 2/L genotypes 
were more frequent among patients with cutaneous mela-
noma (43.6 and 45.1%, respectively) compared with healthy 
controls [29.6 and 30.6%, respectively; odds ratio (OR), 1.84; 
CI, 1.22-2.77; P=0.003; and OR, 1.66; CI, 1.24-2.79; P=0.002, 
respectively]. Conversely, the IL‑1RN-VNTR 1/1 genotype was 
less frequent among melanoma cases (45.9%) compared with 
healthy controls (57.9%; OR, 0.62; CI, 0.41-0.92; P=0.017). 
Comparison of metastatic vs. non-metastatic melanoma cases 
identified no significant differences. The present study first 
demonstrated that carriage of the 1/1 IL‑1RN-VNTR genotype 
was protective, whereas 1/2 and 2/L was a risk factor for 
patients with cutaneous melanoma vs. healthy controls. The 
short allele 2 was associated with higher expression levels of 
IL‑1RA, a potent competitive inhibitor of the proinflammatory 
cytokines IL-1α and IL-1β. VNTR-IL‑1RN polymorphism may 
affect susceptibility to melanoma and, thus, it is a potential 
novel diagnostic biomarker for melanoma. The present study 
increased the understanding of genetic melanoma suscepti-
bility/carcinogenesis, and may indicate novel strategies in the 
personalized prevention of cutaneous melanoma.
Introduction
Factors that affect cutaneous melanoma need to be addressed 
and molecular genetic studies appear promising for a preci-
sion/personalized medicine approach (1-3). A growing body of 
data indicates that besides exposure to ultraviolet (UV) radia-
tion, especially intermittent sun exposure (4), sunburns (4,5), and 
fair skin (4-6), other factors including vitamin D (2,3,7), poly-
chlorinated biphenyls (8), host inflammatory responses (9,10), 
geographical factors (5,6,11,12), the lifestyle (11-13), and genetic 
background can also play a role (1-3,14). Melanoma has a rate of 
22.0 in males and 18.3 in females per 100,000/year (standard-
ized for European population) in Italy (15), and higher incidence 
rates (32.5/100,000/year in males; 23.7/100,000/year in females) 
have been recorded in Friuli Venezia Giulia (FVG) (15), a 
Region located in Northeast Italy at the border with Austria 
and Slovenia. The incidence of melanoma in Italy shows an 
increasing trend (15), Northeast Italy has the highest prevalence 
of melanoma (16), and the FVG Region has the highest rate of 
hospitalization for melanoma in Italy (17).
The interleukin 1 alpha (IL-1α) and IL-1 beta (IL-1β) 
cytokines and the specific receptor antagonist (IL-1RA) 
are components of the interleukin 1 family (18). IL-1α and 
IL-1β are involved in several physiological and pathological 
diseases (18,19), modulating the immune response to patho-
genesis and tissue injuries. Moreover, these cytokines have 
a role in the promotion of cancer‑associated inflammation 
paradoxically both as protective or favoring cancer/metastasis 
onset (19,20). IL-1RA neutralizes IL-1α and IL-1β action by 
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binding to the IL-1 receptors (IL-1R type I, IL-1R1 and type II, 
IL-1R2) without causing any signaling transduction (18). This 
prevents the IL-1α and IL-1β induced cascade of kinases that 
activates NF-kB and cyclooxygenase-2 (COX-2) following 
IL-1 (either α or β) binding to IL-1R1 (18). The IL-1 family 
of cytokines and receptors is involved in a broad spectrum 
of immunological and inflammatory responses including 
activation of lymphocytes (18‑22). Specifically, IL‑1 cytokines 
promote increased levels of the main chemokine IL-8 (CXCL8) 
and consequently activate recruitment of neutrophils (23,24). 
An in vitro human cellular study showed that IL-1RA inhibits 
CXCL8 release (24). Interestingly, a recent research in myeloid 
cells found that inflammasomes/IL-1 pathways induce the 
expression of the programmed death-ligand 1 (PD-L1) on 
tumor cells, which is an immune checkpoint molecule used 
as target of melanoma therapy (25,26). Furthermore, blocking 
IL-1 receptor with IL-1RA or anti-IL-1R1 antibody inhibits 
tumor growth and metastasis accompanied by decreased 
accumulation of myeloid cells and expression of the PD-L1 
molecule (25).
Currently, inflammation and specific IL-1 targeting as 
treatment of cancer is an active area of experimental and 
clinical research (18,20,27). IL-1 mediated inflammation 
is proposed to contribute to the development and progres-
sion of some cancers including melanoma (28). IL-1 appear 
to act at different levels in tumor initiation and progression, 
including driving chronic non‑resolving inflammation, tumor 
angiogenesis, activation of the IL-17 pathway, induction of 
myeloid-derived suppressor cells and macrophage recruitment, 
invasion and metastasis (20). The effects of IL-1 cytokines are 
pleiotropic so that any shift of the biological balance between 
agonistic and antagonistic signals has the potential to cause 
a disease (19). Notably, the role of IL-1RA in cancer has 
been studied in different types of tumors showing effects on 
survival and progression (18-22).
Increasing evidence showed that genetic polymorphisms 
of IL-1 family members can affect susceptibility to disease. 
Human IL-1RA gene (IL‑1RN) is located in chromosome 2, 
specifically 2q13‑2q21 (29,30). Current studies and meta‑anal-
yses evaluated the role of a variable number of tandem 
(VNTR) 86-bp repeats located in intron 2 of the IL‑1RN gene 
in relation to various diseases and cancers, particularly gastric 
cancer (31‑33). Specifically, the IL‑1RN allele 2 (IL‑1RN*2, 
constituted of two 86-bp repeats also denoted as short allele) 
has been associated with increased cancer risk in heterozygous 
subjects (33). Nonetheless, IL‑1RN VNTR polymorphism roles 
in cancer still require further study as inconsistent results have 
been obtained in cancers of different tissue origins (33).
So far, only one German study assessed the role of 
IL‑1RN VNTR polymorphism in 97 melanoma patients and 
343 controls (34). No significant findings were obtained, the 
heterozygous 1/2 genotype was found in 28.8% of advanced 
melanoma patients vs. 39.6% of healthy controls; P=0.06 (34).
Pathways underlying the relationship of IL‑1RN VNTR 
and melanoma currently poses an interesting new challenge 
in melanoma research (1,34) also by considering the potential 
roles of IL-1RA in modulating PD-1/PD-L1 (25).
Progress in the understanding of melanoma risk factors, 
genomics, and molecular pathogenesis may drive advances in 
precision medicine applied to melanoma (1-3,35,36).
In light of these observations, we explored IL‑1RN VNTR 
polymorphism and its association with cutaneous malignant 
melanomas, specifically those with metastatic melanoma 
(MetM) vs. non-metastatic melanoma (NMetM) and vs. 
healthy controls.
Materials and methods
Population. Enrolment and clinical visits of all study 
participants were performed at the Udine University-Hospital 
Dermatology Clinic. Diagnostic procedures were carried out 
according to routine protocols. The Udine Institutional Ethical 
Committee approved the study protocol, which was conducted 
according to the Declaration of Helsinki. All participants 
were alive during enrolment in the study and signed a written 
informed consent.
Using a case-control design, the study consecutively enrolled 
133 (age range of 31-87 years) unrelated patients (hospitalized 
or outpatients) of both sexes with documented cutaneous 
melanoma diagnosis and 382 (age range of 31-87 years) 
asymptomatic healthy controls of both sexes, which were 
matched for age and ancestry with melanoma cases. Inclusion 
criteria for both melanoma cases and healthy controls were as 
follows: Caucasian resident in FVG Region, at least two Italian 
grandparents born in FVG Region (or Austro-Hungarian 
territory before World War I) as described (2,3). Due to the 
demonstrated association of IL‑1RN VNTR with high-grade 
athleticism, athletes were excluded both from melanoma cases 
and healthy controls as described (37). Further, exclusion 
criteria for healthy controls included the following: any kind 
of lifelong malignant or benign tumor, first‑grade relatives 
with a history of melanoma, and major chronic diseases, such 
as autoimmune diseases including type 1 diabetes. Among 
healthy controls 268 subjects were previously studied (37).
Melanoma was diagnosed using immunohistological 
findings obtained after surgical excision of nevi with clinical 
and dermoscopic characteristics suggesting the presence 
of malignancy. Classification of melanoma stages was 
performed by clinical/histological/radiological findings, 
as described (38,39), which was our routine in the period 
of the study whose patient enrollment was completed on 
December 2017. Inclusion criteria for case-patients comprised 
only cutaneous not mucosal melanomas. For patients with 
multiple melanomas, the major melanoma characteristics were 
accounted for in study analyses according to the histological 
assessment of major primary tumor (T) grading.
Each participant answered a questionnaire, which was 
used to collect data on demographic characteristics, medical 
and family history of melanoma, smoking habits, and history 
of sunburns as described (2). Phototype was assessed by 
Fitzpatrick criteria (39). BMI was determined by weight (kg) 
divided by squared height (m2); BMI >30 kg/m2 was considered 
an indicator of obesity.
Genetic analysis of the VNTR IL‑1RN polymorphism. 
VNTR IL‑1RN polymorphism was determined, as previously 
described (40) after extraction of genomic DNA from ethyl-
enediaminetetraacetic-acid-treated venous blood samples (41). 
The IL‑1RN intron 2 VNTR polymorphism (rs2234663; also 
indicated as rs380092) was analyzed using 5'-CTC AGC AAC 
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ACT CCT AT-3' and 5'-TCC TGG TCT GCA GGT AA-3' as 
primers (37,40). The PCR products of 412-bp (allele 1 corre-
sponding to 4 repeats of the 86-bp region), 240-bp (allele 2, 2 
repeats also defined as short allele), 498‑bp (allele 3, 5 repeats), 
326-bp (allele 4, 3 repeats), 584-bp (allele 5, 6 repeats) were 
analyzed by electrophoresis on 10% acrylamide gel stained 
with ethidium bromide (40). Alleles with three or more 86-bp 
repeats were denoted as long (L) alleles (37).
Statistical analysis. Continuous variables were expressed as 
a mean ± standard deviation, and Mann-Whitney U test was 
performed for comparison. Odds ratios (ORs) and 95% confi-
dence intervals (CIs) were calculated for categorical variables, 
and P values for two-sided Pearson's chi-squared or Fisher's 
exact test were reported as was appropriate.
P<0.05 was considered to indicate a statistically significant 
difference and P≤0.10 indicates a tendency to be significant. 
Statistical software SPSS for Windows (SPSS Inc., Chicago, 
IL, USA) was used.
Results
Study subjects. All 515 (133 cutaneous melanoma patients and 
382 healthy controls) study subjects were Italian Caucasian 
residents in Northeast Italy. Melanoma cases and healthy 
controls did not differ for age.
Comparison of VNTR IL‑1RN genotypes in cutaneous mela‑
noma patients and healthy controls (as shown in Table I). 
In all 515 study subjects (data shown in Table SI), the most 
frequent IL‑1RN allele was allele 1 (IL‑1RN*1, frequency 
was 72.9%), followed by allele 2 (IL‑1RN*2, frequency was 
24.5%) and by allele 3 (IL‑1RN*3, frequency was 2.5%). 
The rare heterozygous genotype 1/4 was found in one MetM 
patient, and 1/5 genotype was found in one NMetM patient, 
finally, the rare homozygous 3/3 was found in one healthy 
control.
Homozygous 1/1 genotype was less frequent in mela-
nomas than in healthy control subjects (OR=0.62, P=0.017). 
Conversely, heterozygous 1/2 genotype was almost twice more 
frequent in melanomas than in healthy patients (OR=1.84, 
P=0.003). No differences were observed for 1/3, 2/2, and 
2/3 genotypes. The group of all heterozygous genotypes 
containing the short allele 2 and one of the long alleles 1, 3, 
4, 5 (designed in the literature as 2/L genotype) (33,37) had 
OR=1.66, P=0.002 for melanomas compared with healthy 
controls. The group including all genotypes containing the 
short allele 2 (heterozygous 2/L plus homozygous 2/2 geno-
types) was more frequent in melanoma patients than in healthy 
controls (OR=1.53, P=0.036).
As shown in Table I, frequency of allele 1, 2, and 3 did 
not significantly differ between melanoma and healthy groups, 
although carriers of allele 1 were slightly less frequent among 
melanoma patients (70.3%) than healthy controls (74.3%), 
OR=0.82, P=0.199, whereas carriers of the allele 2 were 
slightly more frequent among melanoma patients (26.3%) than 
healthy controls (23.2%), OR=1.18, P=0.300.
Comparisons of IL‑1RN VNTR genotypes in MetM and 
NMetM cutaneous melanoma patients and healthy controls 
(as shown in Table II). The VNTR IL‑1RN genotypes were not 
associated with the metastatic grade of cutaneous melanoma 
as illustrated in Table II by comparison of MetM with NMetM 
patients.
By comparison of 61 MetM patients with healthy controls, 
1/1 genotype was protective (OR=0.58, P=0.047) and 1/2 was 
at risk (OR=1.77, P=0.042), the group of 2/L genotypes showed 
a tendency at risk (OR=1.68, P=0.063).
By comparison of 72 NMetM patients with healthy 
controls, the 1/2 and 2/L genotypes were at risk (OR=1.90, 
P=0.013, and OR=2.03, P=0.006, respectively).
The frequency of allele 1, 2, and 3 did not differ between 
groups as shown in Table II.
Primary demographic and clinical characteristics of mela‑
noma patients and comparison between VNTR IL‑1RN 2/L 
and other remaining genotypes (as shown in Table III). Main 
demographic and clinical characteristics of the 133 melanoma 
patients are described in Table III. We examined in detail the 
differences between heterozygous carriers of the short allele 2 
(2/L group, n=60) and the other remaining genotypes (non-2/L 
group, n=73) in melanoma patients. No differences were noted 
between groups, however, the frequency of patients with 
a number of body nevi >50 tended to be higher in 2/L than 
non-2/L carriers (58.3% vs. 42.5%, OR=1.90, P=0.069).
In a further analysis (data are not shown) by comparison 
of 2/L carriers with L/L carriers (n=68) among melanoma 
patients, still non significant differences were noted, however, 
frequency of patients with a number of body nevi >50 tended to 
be higher in 2/L than L/L carriers (58.3% vs. 42.6%, OR=1.88, 
CI=0.93-3.80, P=0.077).
Complete questionnaire data including body nevi number 
were available for 114 healthy control subjects; no significant 
differences were noted for a nevi number >50 by comparing 
2/L vs. all other remaining genotypes (12/40, 30.0% vs. 25/74, 
33.8%, OR=0.84, CI=0.37-1.93, P=0.680), and by comparing 
2/L vs. L/L (12/40, 30.0% vs. 23/66, 34.8%, OR=0.80, 
CI=0.34-1.86, P=0.607).
Discussion
IL‑1RA has been implicated in oncogenesis as mice deficient 
in IL-1RA develop the disease in response to carcinogens (42). 
IL-1RA by binding to IL-1R1 strongly modulates the action 
of IL-1 (IL-1α and IL-1β) cytokines, which in turn can induce 
expression of hundreds of genes, including themselves (via a 
positive feedback loop) (43).
IL‑1RN VNTR polymorphism. IL‑1RN is considered an impor-
tant ‘hub’ gene in melanoma research (1). Previous studies 
found associations of the short IL‑1RN*2 allele (two 86-bp 
repeats) with a variety of epithelial‑related chronic inflamma-
tory diseases including psoriasis, scleroderma, alopecia areata, 
lichen sclerosus, systemic lupus erythematosus, and ulcerative 
colitis (44).
The number of 86-bp repeats in the VNTR IL‑1RN 
polymorphism, which is located in intron 2, does not alter 
the encoded amino acid sequence of IL-1RA, but may be of 
functional significance as the repeated sequences contain 
putative binding sites for transcription factors (45,46). A 
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general correlation between IL‑1RN*2 allele and the presence 
of autoinflammatory disease strongly supports a role of VNTR 
IL‑1RN polymorphism in the control of the inflammatory 
response (46).
We observed a general distribution of IL‑1RN VNTR 
genotypes (1/1, 54.8%; 1/2, 33.2%; 1/3, 3.5%; 2/2, 6.8%; 
2/3, 1.2%; 1/4, 0.2%; 1/5, 0.2% and 3/3, 0.2%) among the 
515 Italian study subjects roughly in agreement with other 
investigations (33,34,40).
Notably, in our study, nearly twofold higher frequency 
of 1/2 VNTR IL‑1RN genotype was observed in melanoma 
patients (43.6%) compared with healthy controls (29.6%), 
OR=1.84, P=0.003. This OR value became slightly lower (but 
still statistically significant) by grouping all heterozygous 
genotypes containing the short 2 allele and one long allele (2/L 
group, OR=1.66, P=0.002), and all carriers of allele 2 (2/L+2/2) 
(OR=1.53, P=0.036). We observed that the 1/2 genotype was 
still at risk by comparing separately the subgroups of metastatic 
Table I. Genotype frequencies of IL‑1RN VNTR in all 515 study subjects and comparison of 133 patients with melanoma with 
382 healthy controls.
IL‑1RN VNTR All subjects All patients with Healthy controls OR P-value
genotype/allele (n=515) (%) melanoma (n=133) (%) (n=382) (%) (95% CI) Melanoma vs. Control
1/1 282 (54.8) 61 (45.9) 221 (57.9) 0.62 (0.41-0.92) 0.017
1/2 171 (33.2) 58 (43.6) 113 (29.6) 1.84 (1.22-2.77) 0.003
1/3 18 (3.5) 5 (3.8) 13 (3.4) 1.11 (0.39-3.17) 0.789
2/2 35 (6.8) 5 (3.8) 30 (7.9) 0.46 (0.17-1.21) 0.106
2/3 6 (1.2) 2 (1.5) 4 (1.0) 1.44 (0.26-7.97) 0.651
2/L (1/2 and 2/3)a 177 (34.4) 60 (45.1) 117 (30.6) 1.66 (1.24-2.79) 0.002
1/2 and 2/2 and 2/3 and 2/4 212 (41.2) 65 (48.9) 147 (38.5) 1.53 (1.03-2.27) 0.036
1/3 and 2/3 and 3/3b 25 (4.9) 7 (5.3) 18 (4.7) 1.12 (0.46-2.75) 0.799
Allele 1 755 (73.3)c 187 (70.3)c 568 (74.3) 0.82 (0.60-1.11) 0.199
Allele 2 247 (24.0) 70 (26.3) 177 (23.2) 1.18 (0.86-1.63) 0.300
Allele 3 26 (2.5)d 7 (2.6) 19 (2.5)d 1.06 (0.44-2.55) 0.897
aHeterozygous subjects containing the short allele 2 and one long allele (1, 3, 4 and 5) are denoted as 2/L according the literature (33). 
bHomozygous genotype 3/3 was present in only one healthy subject. cOne metastatic patients had genotype 1/4, and one non-metastatic patient 
had genotype 1/5. dOne healthy subject had genotype 3/3. IL‑1RN, interleukin-1 receptor antagonist gene; OR, odds ratio; VNTR, variable 
number tandem repeat.
Table II. Genotype frequencies of IL‑1RN VNTR comparisons of 61 patients with MetM and 72 patients with NMetM and 382 
healthy controls.
IL‑1RN VNTR MetM NMetM ORa  ORb  ORc
genotype/allele (n=61) (%) (n=72) (%) (95% CI) P-valuea (95% CI) P-valueb (95% CI) P-valuec
1/1 27 (44.3) 34 (47.2) 0.89 (0.45-1.76) 0.733 0.58 (0.34-1.00) 0.047 0.65 (0.39-1.08) 0.095g
1/2 26 (42.6) 32 (44.4) 0.93 (0.47-1.85) 0.833 1.77 (1.02-3.07) 0.042 1.90 (1.14-3.18) 0.013
1/3 3 (4.9) 2 (2.8) 1.81 (0.29-11.2) 0.660 1.47 (0.41-5.31) 0.472 0.81 (0.18-3.67) 1.000
2/2 4 (6.6) 1 (1.4) 4.98 (0.54-45.8) 0.179 0.82 (0.28-2.42) 1.000 0.16 (0.02-1.23) 0.043
2/3 0 (-) 2 (2.8) 0.97 (0.93-1.01) 0.500 0.99 (0.98-1.00) 1.000 2.70 (0.48-15.0) 0.243
2/L (1/2 and 2/3)f 26 (42.6) 34 (47.2) 0.83 (0.42-1.65) 0.595 1.68 (0.97-2.92) 0.063g 2.03 (1.21-3.38) 0.006
1/2 and 2/2 and 30 (49.2) 35 (48.6) 1.02 (0.52-2.02) 0.948 1.55 (0.90-2.66) 0.113 1.51 (0.91-2.51) 0.108
2/3 and 2/4
1/3 and 2/3 and 3/3 3 (4.9) 4 (5.5) 0.88 (0.19-4.09) 1.000 1.05 (0.30-3.66) 1.000 1.19 (0.39-3.62) 0.764
Allele 1 84d (68.9) 103e (71.5) 0.88 (0.52-1.49) 0.634 0.76 (0.50-1.16) 0.201 0.87 (0.58-1.29) 0.480
Allele 2 34 (27.9) 36 (25.0) 1.16 (0.67-2.00) 0.596 1.28 (0.83-1.97) 0.258 1.10 (0.73-1.67) 0.634
Allele 3 3 (2.5) 4 (2.8) 0.88 (0.19-4.02) 1.000 0.99 (0.29-3.39) 1.000 1.12 (0.37-3.34) 0.774
aComparison between MetM and NMetM. bComparison between MetM and healthy controls. cComparison between NMetM and healthy 
controls. dOne metastatic patients had genotype 1/4. eOne non-metastatic patient had genotype 1/5. fHeterozygous subjects containing the short 
allele 2 and one long allele are denoted as 2/L in the literature (33). gSignificant tendencies. IL‑1RN, interleukin-1 receptor antagonist gene; 
MetM, metastatic melanoma; NMetM, non-metastatic melanoma; OR, odds ratio; VNTR, variable number tandem repeat.
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Table III. Clinical characteristics of 133 patients with melanoma consecutively enrolled, and comparison between the two genetic 
subgroups of IL‑1RN VNTR 2/L genotypes (n=60) and all other genotypes (n=73).
 All patients with 2/L genotype Non-2/L OR (CI),  P-value, 
Characteristics melanoma (n=133) (n=60) genotypes (n=73) 2/L vs. Non-2/L 2/L vs. Non-2/L
Age <50 years, n (%) 29 (21.8) 13 (21.7) 16 (21.9)  0.98 (0.43-2.25) 0.972
Age at study enrolment,  60.8±12.7 61.1±12.9 60.7±12.7 - 0.788a
years, mean ± SD
Age at melanoma diagnosis,  54.2±13.7 54.4±13.5 54.0±14.0 - 0.781a
years, mean ± SD
Time from melanoma diagnosis,  6.7±4.1 6.7±4.4 6.6±3.9 - 0.754a
years, mean ± SD
Females, n (%) 58 (43.6) 26 (43.3) 32 (43.8)  0.98 (0.49-1.95) 0.954
Males, n (%) 75 (56.4) 34 (56.7) 41 (56.2)  1.02 (0.51-2.03) 0.954
All grand-parents born in FVG 96 (72.2) 43 (71.7) 53 (72.6) 0.95 (0.45-2.04) 0.905
BMI, kg/m2, mean ± SD 25.8±3.97 26.1±4.0 25.6±4.0 - 0.643a
BMI >30 kg/m2, n (%) 22 (16.5) 11 (18.3) 11 (15.1)  1.26 (0.51-3.16) 0.614
High school, n (%) 60 (45.1) 27 (45.0) 33 (45.2)  0.99 (0.50-1.97) 0.981
Graduation, n (%) 15 (11.3) 5 (8.3) 10 (13.7)  0.57 (0.18-1.78) 0.330
Present smoker, n (%) 12 (9.0) 4 (6.7) 8 (11.0)  0.58 (0.17-2.03) 0.390
Past smoker, n (%) 53 (39.8) 25 (41.7) 28 (38.4)  1.15 (0.57-2.30) 0.698
Ever smoker, n (%) 65 (48.9) 29 (48.3) 36 (49.3)  0.96 (0.48-1.90) 0.910
≥20 cigarettes ever in all  40 (30.1) 17 (28.3) 23 (31.5)  0.86 (0.41‑1.81) 0.691
subjects, n (%)
Phototype number 2.4±0.7 2.5±0.7 2.3±0.6 - 0.146a
Phototype 1 and 2, n (%) 77 (57.9) 30 (50.0) 47 (64.4)  0.55 (0.28-1.11) 0.095g
Nevi > 50, n (%) 66 (49.6) 35 (58.3) 31 (42.5)  1.90 (0.95-3.79) 0.069g
Burns over 5, n (%) 71 (53.4) 32 (53.3) 39 (53.4)  1.00 (0.50-1.98) 0.992
NMetM, n (%) 72 (54.1) 34 (56.7) 38 (52.1)  1.20 (0.61-2.39) 0.595
Stage I, n (%) 52 (39.1) 24 (40.0) 28 (38.4)  1.07 (0.53-2.16) 0.847
Stage II, n (%) 19 (14.3) 9 (15.0) 10 (13.7)  1.11 (0.42-2.94) 0.831
Stage III, n (%) 38 (28.6) 19 (31.7) 19 (26.0)  1.32 (0.62-2.80) 0.474
Stage IV, n (%) 24 (18.0) 8 (13.3) 16 (21.9)  0.55 (0.22-1.39) 0.200
Trunk, n (%) 75 (56.4) 36 (60.0) 39 (53.4)  1.31 (0.65-2.61) 0.447
Upper limb, n (%) 9 (6.8) 5 (8.3) 4 (5.5)  1.57 (0.40-6.12) 0.731
Lower limb, n (%) 28 (21.1) 11 (18.3) 17 (23.3)  0.74 (0.32-1.73) 0.486
Hands/feet, n (%) 8 (6.0) 3 (5.0) 5 (6.8)  0.72 (0.16-3.13) 0.729
Head/neck, n (%) 13 (9.8) 5 (8.3) 8 (11.0)  0.74 (0.23-2.39) 0.612
Superficial spreading, n (%) 70 (52.6) 31 (51.7) 39 (53.4)  0.93 (0.47‑1.85) 0.840
Nodular, n (%) 45 (33.8) 23 (38.3) 22 (30.1)  1.44 (0.70-2.96) 0.320
Acral lentiginous, n (%) 5 (3.8) 1 (1.7) 4 (5.5)  0.29 (0.03-2.69) 0.378
Lentigo maligna, n (%) 2 (1.5) 0 (-)b 2 (2.7)  0.97 (0.94-1.01) 0.501
Spitzoide, n (%) 5 (3.8) 4 (6.7) 1 (1.4)  5.14 (0.56-47.3) 0.174
Others, n (%) 9 (6.8) 3 (5.0) 6 (8.2)  0.59 (0.14-2.46) 0.512
Breslow thickness, mm, mean ± SD 2.05±1.85 2.17±2.12 1.95±1.61 - 0.871a
Clark I, n (%) 2 (1.5)c 0 (-)b,d 2 (2.8)  0.97 (0.93-1.01) 0.501
Clark II, n (%) 32 (24.4)c 15 (25.4)d 17 (23.6)e 1.10 (0.50-2.45) 0.810
Clark III, n (%) 24 (18.3)c 9 (15.3)d 15 (20.8)e 0.68 (0.27-1.70) 0.411
Clark IV, n (%) 67 (51.1)c 33 (55.9)d 34 (47.2)e 1.42 (0.71-2.83) 0.321
Clark V, n (%) 4 (3.1)c 1 (1.7)d 3 (4.2)e 0.40 (0.04-3.92) 0.627
Ulceration, n (%) 51 (38.3) 26 (43.3) 25 (34.2)  1.47 (0.73-2.97) 0.284
Mitosis >1, n (%) 83 (63.4)c 39 (66.1)d 44 (61.1)e 1.24 (0.60-2.54) 0.555
Regression, n (%) 20 (15.3)c 9 (15.3)d 11 (15.3)e 1.00 (0.38-2.60) 0.997
Brisk positive TILs, n (%) 38 (29.0)c 17 (28.8)d 21 (29.2)e 0.98 (0.46-2.10) 0.965
Non-brisk TILs, n (%)  47 (35.9)c 25 (42.4)d 22 (30.6)e 1.67 (0.81-3.43) 0.161
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melanomas (OR=1.77, P=0.042) and non-metastatic melanoma 
(OR=1.90, P=0.013) with healthy controls. Heterozygous 2/L 
carriers were at increased risk when comparing NMetM vs. 
healthy controls (OR=2.03, P=0.006), whereas a tendency was 
observed comparing MetM vs. healthy controls (OR=1.68, 
P=0.063).
Homozygous VNTR IL‑1RN 1/1 carriers were at reduced 
risk comparing melanoma cases with healthy controls 
(OR=0.62, P=0.017). The 1/1 genotype was protective for 
the subgroup of metastatic melanomas (OR=0.58, P=0.047), 
however, only a tendency for protection was observed for 
non-metastatic melanomas compared to healthy controls 
(OR=0.65, P=0.095).
By a further analysis, we demonstrated that among 
melanoma patients the 1/2 and 2/L genotypes frequencies 
did not differ between MetM and NMetM patients. The 2/2 
genotype was more frequent in MetM (6.6%) than in NMetM 
(1.4%) patients, however, such difference was not statistically 
significant (OR=4.98, P=0.179).
Our study shows in detail that among melanoma patients, 
the 2/L genotypes did not differ from the remaining genotypes 
for demographic characteristics, gender, known risk factors, 
staging, location, and deepening of melanoma. However, 
we observed that among melanomas 58.3% of 2/L carries 
had more than 50 body nevi vs. 42.5% of non-2/L carriers 
OR=1.90, P=0.069. This tendency result should be confirmed 
in enlarged studies. A possible association of 2/L genotype 
with an increased number of body nevi could explain the 
higher risk of 2/L carriers for melanoma because an elevated 
body nevi number is a recognized risk factor for melanoma.
This study is the first investigation of VNTR IL‑1RN 
polymorphism in Italian melanoma patients, and the second 
one on this polymorphism and melanoma after the study of 
Broer and colleagues (34). Broer and colleagues performed 
a study in aggressive melanomas having stage III or higher 
(in other words all metastatic melanomas) and 343 healthy 
controls finding a frequency of allele IL‑1RN*1 of 73.2% in 
melanomas and of 71.7% in healthy controls, a frequency 
of allele IL‑1RN*2 of 23.7% in melanomas and of 28.3% in 
healthy controls, whereas the rare allele 3 was found in 2 mela-
noma patients, and allele 4 was found in 4 melanoma patients. 
Those data are roughly in line with our allele frequency data. 
However, the German study (34) did not observe statistically 
significant differences between aggressive melanomas and 
healthy controls for VNTR IL‑1RN genotypes; indeed the 
frequency of 1/2 genotype tended to be even lower in aggres-
sive melanomas than controls (28.8% vs. 39.6%, P=0.06). At 
variance, in our Italian melanoma group, the frequency of 1/2 
genotype was 1.5-fold higher (43.6%) than in German patients. 
Such a difference could derive by different ethnic back-
ground (33) and/or by selection of melanoma cases. Moreover, 
the high rate of 1/2 genotype in the German healthy controls 
could be due to different inclusion/exclusion criteria in respect 
to our study, for example, in our study we excluded high-grade 
athletes because they have an increased frequency of VNTR 
1/2 genotype (37).
The 2/L genotype data of our study are consistent with 
studies relative to other cancers (33,47). The disproportionate 
levels of IL-1RA could activate balancing elevation of other 
factors in the complex network of IL-1 family cytokines and 
receptors that lead to fine tuning of immune response (19,48,49).
Despite a large number of studies, the association of VNTR 
IL‑1RN with cancer still shows some inconsistencies (33). The 
association of the VNTR IL‑1RN polymorphism with cancer 
was examined by Zhang and colleagues (33) who performed 
a meta-analysis including 14,854 cases and 19,337 controls 
from 71 published case-control studies. Genotypic analysis 
showed significant associations in gastric cancer (2/L vs. 
L/L, OR=1.22, CI=1.05-1.41). However, in breast cancer, 2/L 
vs. L/L was protective (OR=0.74, CI=0.58-0.93), whereas 
in hepatocellular, cervical and lung cancer data were not 
significant. Moreover, such positive association with cancer 
Table III. Continued.
 All patients with 2/L genotype Non-2/L OR (CI),  P-value, 
Characteristics melanoma (n=133) (n=60) genotypes (n=73) 2/L vs. Non-2/L 2/L vs. Non-2/L
TILs absence, n (%) 45 (34.4)c 17 (28.8)d 28 (38.9)e 0.64 (0.30-1.33) 0.227
Microsatellitosis, n (%) 5 (3.8)c 2 (3.4)d 3 (4.2)e 0.81 (0.13-5.00) 1.000
Epithelioid variant, n (%) 37 (28.0)f 14 (23.3) 23 (31.9)e  0.65 (0.30-1.41) 0.273
Fusate variant, n (%) 13 (9.8)f 6 (10.0) 7 (9.7)e  1.03 (0.33-3.25) 0.957
Small cell variant, n (%) 2 (1.5)f 0 (-)b 2 (2.8)e  0.97 (0.93-1.01) 0.500
More than 1 melanoma, n (%) 20 (15.0) 10 (16.7) 10 (13.7)  1.26 (0.49-3.26) 0.634
Additional non-melanoma skin  22 (16.5) 7 (11.7) 15 (20.5)  0.51 (0.19-1.35) 0.170
cancer, n (%)
Additional non-skin cancer, n (%) 29 (21.8) 11 (18.3) 18 (24.7)  0.69 (0.29-1.59) 0.379
Concurrent thyroid disease, n (%) 16 (12.0) 8 (13.3) 8 (11.0)  1.25 (0.44-3.56) 0.675
Melanoma familiarity, n (%)  18 (13.5) 10 (16.7) 8 (11.0)  1.62 (0.60-4.42) 0.338
aTwo-tailed Mann-Whitney U-test. bUncountable because the group contained no subjects. cData were available for 131 patients. dData were 
available for 59 patients. eData were available for 72 patients. fData were available for 132 patients. gSignificant tendencies. BMI, body mass 
index; FVG, Friuli Venezia-Giulia; IL‑1RN, interleukin‑1 receptor antagonist gene; OR, odds ratio; TILs, tumor‑infiltrating lymphocytes; 
VNTR, variable number tandem repeat.
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was stronger in Asian than in Caucasian population (33). The 
inconsistency is likely caused in part by the differences in 
the subject ethnicity, sample sizes, disease stages, and cancer 
types for studies. It is apparent that further studies with large 
homogeneous patient populations will be needed to validate 
the association between VNTR IL‑1RN gene polymorphism 
and human cancer.
Allele 2 of VNTR IL-1RA polymorphism (IL‑1RN*2) is 
considered to have modulatory effects on inflammatory response, 
however, evidence on final effects associated to IL‑1RN*2 are 
contradictory (48,50,51). Evaluation of comprehensive effects 
of IL‑1RN*2 is complicated by the concurrent modulation of 
the anti‑inflammatory IL‑1RA and the pro‑inflammatory IL‑1 
cytokine levels (48,52). The presence of the IL‑1RN*2 has 
been associated with enhanced IL-1β production in vitro (48), 
and increased inflammatory response (31,51). Indeed, IL‑1RA 
plasma levels are coordinately regulated by both IL-1RA and 
IL-1beta genes (53) indicating a cross-regulation between the 
receptor antagonist and IL-1 cytokine expression (48,49,54). 
Tissue‑specific effects are also possible (33).
According to some studies the carriers of IL‑1RN*2 
have higher IL-1RA levels (53,55,56), and consequently 
the 2 allele effects could down-regulate IL-1 mediated 
pro‑inflammatory signaling pathways by the IL‑1RA blocking 
of IL-1R1 (37,57,58). A recent study (59) showed that indi-
viduals with genotype 2/2 VNTR IL‑1RN exhibited higher 
IL-1RA expression compared to 1/2 and 1/1 genotypes. The 
same study indicated that IL‑1RN*2 might be a risk factor for 
progressive vitiligo (59).
On the basis of such evidence, in IL‑1RN*2 carrier the 
increased IL-1RA expression could provoke a reduced 
anti-tumor immune capacity and could favor the onset of mela-
noma. On the other hand, a study (28) showed that blocking 
of IL-1R1 by treatment with IL-1R1 neutralizing antibody 
or IL-1 pathway-specific siRNAs led to growth arrest in 
IL-1-positive melanoma cells. Furthermore, blocking the IL-1 
pathway increased autophagy in IL-1-positive melanoma cells 
indicating that the endogenous IL-1 system is functional in 
most human melanoma and interrupting its signaling inhibits 
the growth of IL-1-positive melanoma cells (28).
It appears plausible that a low IL-1-related immune 
response (due to moderately elevated IL-1RA as in 2/L 
genotypes) increases the risk to develop melanoma, but, at the 
same time, does not increase or even could reduce the risk 
to develop an aggressive tumor. Such a hypothesis would fit 
with our present findings showing that 2/L genotype increases 
the risk to develop melanoma, but is not more frequent in 
metastatic than non-metastatic melanomas. Furthermore, such 
hypothesis would also fit with Broer et al (34) data showing a 
tendency of lower frequency of 2/L in aggressive melanomas 
than healthy controls.
IL-1R1 receptor activation by IL-1α and/or IL-1β induces 
an array of factors including IL-1, IL-6 (CXCL6), IL-8 
(CXCL8), interferon (IFN) α, β, and γ, defensins, matrix 
metalloproteinases (MMPs), C-reactive protein, etc (18,20,60). 
Thus, the IL-1RA inhibition of IL-1R1 affects several immune 
factors. It is worth to note that IL-1RA can compete with IL-1 
cytokines also for the IL-1R2, which acts as a decoy receptor. 
Of note, anakinra (a recombinant form of IL-1RA used as 
an anti-inflammatory drug in certain diseases) or genetic 
inactivation of the IL-1β-IL-1R1 system can lead to less mela-
noma growth in mice (18,28).
A recent study (61) showed that in MyD88-/- mice 
and in C57BL/6 mice treated with anakinra the relapse 
rates of mice subcutaneous B16 melanoma tumor growth 
significantly increase. This study suggested that IL‑1, via its 
action on neutrophils, promotes the anti‑cancer efficacy of 
ingenol mebutate (a drug approved for the topical treatment 
of actinic keratoses that could ultimately also find utility 
in treating skin cancers), with ingenol mebutate treatment 
causing both IL-1β induction and IL-1α release from 
keratinocytes (61).
Future research should focus on complex gene interactions 
and biological pathways related to the IL-1 family of cytokines 
and receptors and melanoma. Improved comprehension of 
biomolecular immune pathways will support further progress 
in melanoma management (1-3,33,36).
Study limitations and strengths. A strong point of our study is 
the highly defined ethnic background of subjects. This vari-
able is important in genetic studies. Specifically, evidence on 
ethical and geographical variability of genetic polymorphisms 
in IL-1 family genes is growing (23,33). Moreover, variability 
in racial distribution and genetic melanoma susceptibility 
among (and across) different countries suggests that melanoma 
studies should be performed in restricted and well-character-
ized ethnic groups (6,11). On the other hand, our results cannot 
be generalized to populations with different genetic back-
grounds. A strength of this study is detailed clinical data of 
melanoma patients. Limitations of our study include a limited 
sample size in subgroups of patients and high CIs for some 
categorical variables. These limitations could have influenced 
the non‑significant results showed in Table II. Thus, future 
large-scale studies are necessary to better assess the role of 
such variables.
More personalized approach to cancer is a challenge of 
current research (62,63). Personalized boosting of anti-tumor 
immunity in advanced melanomas is a new promising trend 
in the treatment of malignant melanoma. Immunotherapy 
is successful for some patients without relapse or progres-
sion, but many patients undergoing therapy have progressive 
disease (9,64,65). Thus, a better understanding of immune 
factors' modulation contributing to the development of mela-
noma may increase the likelihood of future improvements in 
patient management and melanoma prevention by tailored 
immune modulation modality. IL-1 cytokines and receptors 
including IL-1RA act in a complex balance, which can both 
host protect and harm (19). Our data highlighted that in terms 
of IL‑1RN gene alteration by VNTR in intron 2, IL-1RA 
homeostasis plays roles in cutaneous melanoma. IL‑1RN 2/L 
(mainly constituted by 1/2 genotype) genotype was found 
associated to susceptibility to cutaneous melanoma, whereas 
1/1 was protective. Thus, our findings support an IL‑1 family 
of receptors contribution to the development of malignant 
melanoma, suggesting the value of genetic screening as an 
adjuvant of immune strategies for cancer prevention. Future 
studies should further explore IL‑1RN polymorphisms for their 
inclusion in risk models for individualized prevention/suscep-
tibility/prognosis in the practice of precision medicine applied 
in cutaneous melanoma.
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We first suggest that the heterozygous subjects having 
the short allele IL‑1RN*2 are more prone to cutaneous 
malignant melanoma showing that (innate) immune mecha-
nisms play a role in the susceptibility/pathogenesis of this 
cancer. Interrelationships of IL‑1RN 86-bp VNTR with 
other polymorphisms including those of IL-1β gene (IL-1B) 
are of interest for future research (40,53). IL‑1RN may be a 
candidate gene for melanoma pathogenesis or may possibly be 
a linked marker to other, as yet undefined, genes. However, 
it is tempting to speculate that determination of IL-1 family 
polymorphisms could be used in the future for a personalized 
preventive treatment of healthy subjects at high risk to develop 
melanoma and/or for prognostic evaluation. Notably, IL-1RA 
seems to have roles in PD-L1 regulation, which is a main target 
of immune therapy for advanced melanoma (25). Interestingly, 
in our study IL‑1RN 2/L genotype appears to act as a risk 
factor for melanoma susceptibility independently by conven-
tional risk factors for melanoma, with the possible exception 
of the elevated presence of nevi. Further investigations are 
necessary to extend our findings to also examine different 
ethnic groups (66) and to identify biological pathways related 
to IL‑1RA, which influence skin diseases (67). It is likely that 
cancer treatment and management will be supplemented in 
the future by extensive systematic assessment of DNA path-
ways (1,35,36).
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